Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT003-QbG10 dose-finding study in moderate to severe allergic asthma
2012-003070-39Phase 2Terminated
- Sponsor
- Cytos Biotechnology AG
- Start
- Sep 2012
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of CYT003-QbG10 in allergic asthma (4 arms), sponsored by Cytos Biotechnology AG. Primary endpoint: Change from baseline in Asthma Control Questionnaire score. Started Sep 2012; status: terminated.
02
Drugs
CYT003-QbG10
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2012-003070-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003070-39.